Stella Meireles Siqueira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Stella Meireles Siqueira has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Andreia Cristina de Melo
Brazilian National Cancer Institute (INCA), Division of Clinical Research and Technological Development, Rio de Janeiro, Brazil
3 shared publications - Gabriella Campos-Do-Carmo
Oncological Dermatology Service, Instituto Nacional do Câncer, Rio de Janeiro (RJ), Brazil
3 shared publications - Alexssandra Lima Siqueira dos Santos
Division of Clinical Research and Technological Development, Brazilian National Cancer Institute, Rio de Janeiro, Brazil
2 shared publications - Cícero Martins
Instituto Nacional de Câncer, INCA, Instituto COI, Américas Oncologia, Rio de Janeiro, RJ, Brazil
2 shared publications - Bruna Barroso Gonçalves
Dermatology Service, Universidade Federal Fluminense, Niterói (RJ), Brazil
1 shared publication - Isabele Avila Small
Data Management and Analysis, Instituto Nacional de Cancer, Rio de Janeiro, BRAZIL
1 shared publication
Latest Publications
- Open Access
- 4 January 2024
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 19 (1) , 1-10
The prognostic role of PD-L1 expression and the presence of polyomavirus in Merkel cell carcinoma cases
Background: Merkel cell carcinoma (MCC) comprises a rare malignant primary skin tumor presenting neuroendocrine differentiation. Recently, agents blocking the programmed cell death protein 1 and programmed cell death protein ligand 1 pathway (PD-1/PD-L1) have demonstrated objective and durable tumor regressions in patients presenting advanced MCC. This study aimed to describe the sociodemographic, clinical, and histopathological characteristics of MCC patients, also assessing the prevalence of PD-L1 expression and Merkel cell Polyomavirus (MCPyV), as well as their prognostic roles. Methods: Data from patients diagnosed with MCC between 1996 and 2019 at a reference cancer center in Rio de Janeiro, southeastern Brazil, were evaluated in a retrospective study. Tumor samples were tested for MCPyV and PD-L1 employing immunohistochemistry. Survival analyses were carried out employing the Kaplan–Meier method and curves were compared using the log-rank test. A multiple semiparametric Cox model was used. Values p < 0.05 were considered significant. Results: A total of 65 patients were included in the study, with a mean age at diagnosis of 72 (standard deviation 13.9). A total of 56.9% (37/65) of the patients were male, 86.2% (56/65) were white, and 56.9% (37/64) were illiterate or with incomplete elementary school. MCPyV immunohistochemistry was positive in 29 cases (44.6%) and PD-L1 positivity was ≥ 1% in 42 cases (64.6%). Significant associations between MCPyV and PD-L1 expression ≥ 1% (p = 0.003) and PD-L1 expression ≥ 5% (p = 0.005) were noted. Concerning the multivariate analysis, only education level and advanced MCC stage indicated statistically significant worse progression-free survival. Regarding overall survival (OS), being male, education level and advanced stage comprised risk factors. The estimated OS at 60 months for stages I to III was of 48.9% and for stage IV, 8.9%. Conclusions: This is the first large Brazilian cohort to assess the prevalence of MCPyV in MCC tumors, as well as PD-L1 expression and their associations. No correlations were noted between MCPyV infection or PD-L1 expression and survival rates.
- 4 January 2024
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 19 (1) , 1-10
Open AccessThe prognostic role of PD-L1 expression and the presence of polyomavirus in Merkel cell carcinoma cases
Background: Merkel cell carcinoma (MCC) comprises a rare malignant primary skin tumor presenting neuroendocrine differentiation. Recently, agents blocking the programmed cell death protein 1 and programmed cell death protein ligand 1 pathway (PD-1/PD-L1) have demonstrated objective and durable tumor regressions in patients presenting advanced MCC. This study aimed to describe the sociodemographic, clinical, and histopathological characteristics of MCC patients, also assessing the prevalence of PD-L1 expression and Merkel cell Polyomavirus (MCPyV), as well as their prognostic roles. Methods: Data from patients diagnosed with MCC between 1996 and 2019 at a reference cancer center in Rio de Janeiro, southeastern Brazil, were evaluated in a retrospective study. Tumor samples were tested for MCPyV and PD-L1 employing immunohistochemistry. Survival analyses were carried out employing the Kaplan–Meier method and curves were compared using the log-rank test. A multiple semiparametric Cox model was used. Values p < 0.05 were considered significant. Results: A total of 65 patients were included in the study, with a mean age at diagnosis of 72 (standard deviation 13.9). A total of 56.9% (37/65) of the patients were male, 86.2% (56/65) were white, and 56.9% (37/64) were illiterate or with incomplete elementary school. MCPyV immunohistochemistry was positive in 29 cases (44.6%) and PD-L1 positivity was ≥ 1% in 42 cases (64.6%). Significant associations between MCPyV and PD-L1 expression ≥ 1% (p = 0.003) and PD-L1 expression ≥ 5% (p = 0.005) were noted. Concerning the multivariate analysis, only education level and advanced MCC stage indicated statistically significant worse progression-free survival. Regarding overall survival (OS), being male, education level and advanced stage comprised risk factors. The estimated OS at 60 months for stages I to III was of 48.9% and for stage IV, 8.9%. Conclusions: This is the first large Brazilian cohort to assess the prevalence of MCPyV in MCC tumors, as well as PD-L1 expression and their associations. No correlations were noted between MCPyV infection or PD-L1 expression and survival rates.
- Open Access
- 1 May 2023
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 98 (3) , 277-286
Carcinoma de células de Merkel: epidemiologia, características clínicas, diagnóstico e tratamento de doença rara
- 1 May 2023
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 98 (3) , 277-286
Open AccessCarcinoma de células de Merkel: epidemiologia, características clínicas, diagnóstico e tratamento de doença rara
- Open Access
- 2 March 2023
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 98 (3) , 277-286
Merkel cell carcinoma: epidemiology, clinical features, diagnosis and treatment of a rare disease
- 2 March 2023
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 98 (3) , 277-286
Open AccessMerkel cell carcinoma: epidemiology, clinical features, diagnosis and treatment of a rare disease
- Open Access
- 1 April 2019
- Published by FapUNIFESP (SciELO) in Anais Brasileiros de Dermatologia
- Vol. 94 (2) , 221-223
Vegetative chronic genital herpes with satisfactory response to imiquimod
Vegetative chronic genital herpes is an atypical presentation of herpes simplex 2 that it is usually seen in patients coinfected with human immunodeficiency virus. Clinically, it is characterized by extensive ulcers that evolve to chronification and hypertrophic pseudotumor forms. Antiviral drugs are recommended for the treatment, and acyclovir is the most used one. Foscarnet is the treatment of choice to resistant cases, although treatment failure has been reported. We report a male patient, previously diagnosed with human immunodeficiency virus who developed vegetative chronic genital herpes resistant to acyclovir and successfully treated with imiquimod.
- 1 April 2019
- Published by FapUNIFESP (SciELO) in Anais Brasileiros de Dermatologia
- Vol. 94 (2) , 221-223
Open AccessVegetative chronic genital herpes with satisfactory response to imiquimod
Vegetative chronic genital herpes is an atypical presentation of herpes simplex 2 that it is usually seen in patients coinfected with human immunodeficiency virus. Clinically, it is characterized by extensive ulcers that evolve to chronification and hypertrophic pseudotumor forms. Antiviral drugs are recommended for the treatment, and acyclovir is the most used one. Foscarnet is the treatment of choice to resistant cases, although treatment failure has been reported. We report a male patient, previously diagnosed with human immunodeficiency virus who developed vegetative chronic genital herpes resistant to acyclovir and successfully treated with imiquimod.